MCID: ADN012
MIFTS: 42

Adenocarcinoma in Situ

Categories: Cancer diseases, Endocrine diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Adenocarcinoma in Situ

MalaCards integrated aliases for Adenocarcinoma in Situ:

Name: Adenocarcinoma in Situ 11 43 14 71

Classifications:



External Ids:

Disease Ontology 11 DOID:4943
MeSH 43 D065311
NCIt 49 C4123
SNOMED-CT 68 51642000
UMLS 71 C0334276

Summaries for Adenocarcinoma in Situ

Disease Ontology: 11 An in situ carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary: Adenocarcinoma in Situ is related to early invasive cervical adenocarcinoma and pulmonary adenocarcinoma in situ. An important gene associated with Adenocarcinoma in Situ is KRAS (KRAS Proto-Oncogene, GTPase), and among its related pathways/superpathways are Malignant pleural mesothelioma and Endometrial cancer. The drugs Vaccines and Immunologic Factors have been mentioned in the context of this disorder. Affiliated tissues include cervix, lung and prostate, and related phenotypes are Decreased viability and homeostasis/metabolism

Related Diseases for Adenocarcinoma in Situ

Diseases in the Adenocarcinoma family:

Adenocarcinoma in Situ

Diseases related to Adenocarcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 548)
# Related Disease Score Top Affiliating Genes
1 early invasive cervical adenocarcinoma 32.3 INSM1 CDKN2A
2 pulmonary adenocarcinoma in situ 31.5 TP53 NKX2-1 KRT7 KRAS HRAS EGFR
3 cervical adenocarcinoma 30.5 TP53 MAPK8IP1 KRT7 KRAS INSM1 CEACAM5
4 cervix endometriosis 30.5 MAPK8IP1 CDKN2A
5 endometrial mucinous adenocarcinoma 30.4 KRAS CDKN2A
6 appendix adenocarcinoma 30.1 TP53 KRT7 KRAS HRAS CEACAM5
7 adenocarcinoma 30.1 TP53 NKX2-1 NAPSA KRT7 KRAS HRAS
8 cervical polyp 30.1 MUC6 MAPK8IP1
9 endometrial hyperplasia 30.0 TP53 KRAS CDKN2A
10 exanthem 30.0 KRAS HRAS EGFR ALK
11 barrett esophagus 30.0 TP53 MUC6 KRT7 CDKN2A
12 cystadenoma 30.0 MUC6 KRT7 CEACAM5
13 suppressor of tumorigenicity 3 30.0 TP53 CDKN2A
14 papilloma 29.9 TP53 KRT7 KRAS EGFR CDKN2A
15 endometrial adenocarcinoma 29.9 TP53 KRT7 KRAS EGFR CDKN2A
16 esophagus adenocarcinoma 29.9 TP53 EGFR CDKN2A
17 adenoma 29.8 TP53 MUC6 KRT7 KRAS HRAS CDKN2A
18 endocervical adenocarcinoma 29.7 U2AF1 TP53 MUC6 MAPK8IP1 KRT7 INSM1
19 duodenum adenocarcinoma 29.7 MUC6 KRT7 KRAS HRAS CEACAM5
20 clear cell adenocarcinoma 29.6 TP53 NAPSA KRT7
21 cervical squamous cell carcinoma 29.6 TP53 KRAS EGFR CEACAM5 CDKN2A
22 cystic teratoma 29.6 TP53 NKX2-1 KRT7 CEACAM5
23 benign teratoma 29.5 TP53 NKX2-1 KRT7 CEACAM5
24 gastric adenocarcinoma 29.5 TP53 KRAS HRAS CEACAM5 CDKN2A
25 papillary adenocarcinoma 29.5 TP53 NKX2-1 NAPSA KRT7 KRAS HRAS
26 ovarian mucinous neoplasm 29.5 U2AF1 MUC6 KRT7 KRAS HRAS CEACAM5
27 ductal carcinoma in situ 29.5 TP53 PDPN EGFR CDKN2A
28 endometrial cancer 29.5 TP53 KRT7 KRAS HRAS EGFR CEACAM5
29 colon adenocarcinoma 29.5 TP53 KRAS HRAS EGFR CEACAM5
30 peritoneum cancer 29.5 TP53 KRT7 EGFR CEACAM5 CDKN2A
31 cervix uteri carcinoma in situ 29.5 TP53 PTPRN MAPK8IP1 INSM1 GP5 CDKN2A
32 bronchiolo-alveolar adenocarcinoma 29.4 TP53 NKX2-1 MUC6 KRT7 KRAS HRAS
33 lung cancer susceptibility 3 29.4 U2AF1 TP53 NKX2-1 NAPSA KRT7 KRAS
34 pseudomyxoma peritonei 29.4 TP53 MUC6 KRT7 KRAS CEACAM5
35 cholangiocarcinoma 29.3 TP53 KRT7 KRAS EGFR CEACAM5 CDKN2A
36 teratoma 29.3 TP53 NKX2-1 KRT7 KRAS CEACAM5 CDKN2A
37 colorectal adenocarcinoma 29.3 TP53 KRT7 KRAS HRAS EGFR CEACAM5
38 villous adenoma 29.2 TP53 MUC6 KRT7 KRAS HRAS CEACAM5
39 serous cystadenocarcinoma 29.2 TP53 NAPSA KRT7 KRAS HRAS CDKN2A
40 gallbladder adenocarcinoma 29.2 TP53 PDPN MUC6 KRT7 HRAS CEACAM5
41 lung benign neoplasm 29.1 TP53 NKX2-1 KRT7 KRAS HRAS EGFR
42 squamous cell carcinoma 29.1 TP53 PDPN NKX2-1 KRT7 KRAS HRAS
43 ovary adenocarcinoma 29.0 U2AF1 TP53 KRT7 KRAS HRAS EGFR
44 hemangioma 28.9 TP53 PDPN NKX2-1 KRT7 KRAS EGFR
45 gallbladder disease 28.9 TP53 PDPN KRT7 KRAS HRAS EGFR
46 adenosquamous carcinoma 28.9 PTPRN NKX2-1 MAPK8IP1 KRT7 KRAS INSM1
47 large cell neuroendocrine carcinoma 28.6 TP53 NKX2-1 NAPSA KRT7 KRAS INSM1
48 mucinous adenocarcinoma 28.6 U2AF1 TP53 NKX2-1 NAPSA MUC6 KRT7
49 gallbladder cancer 28.5 TP53 PDPN MUC6 KRT7 KRAS HRAS
50 cervical intraepithelial neoplasia 10.5

Graphical network of the top 20 diseases related to Adenocarcinoma in Situ:



Diseases related to Adenocarcinoma in Situ

Symptoms & Phenotypes for Adenocarcinoma in Situ

GenomeRNAi Phenotypes related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

25 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.68 EGFR HRAS KRAS
2 Decreased viability GR00055-A-2 9.68 EGFR HRAS KRAS
3 Decreased viability GR00055-A-3 9.68 KRAS
4 Decreased viability GR00106-A-0 9.68 KRAS
5 Decreased viability GR00221-A-1 9.68 ALK CDKN2A EGFR HRAS KRAS
6 Decreased viability GR00221-A-2 9.68 HRAS KRAS
7 Decreased viability GR00221-A-3 9.68 CDKN2A HRAS
8 Decreased viability GR00221-A-4 9.68 ALK CDKN2A EGFR
9 Decreased viability GR00249-S 9.68 ALK
10 Decreased viability GR00301-A 9.68 KRAS
11 Decreased viability GR00381-A-1 9.68 KRAS

MGI Mouse Phenotypes related to Adenocarcinoma in Situ:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.36 ALK CDKN2A CEACAM5 CLDN1 CLDN10 EGFR
2 growth/size/body region MP:0005378 10.18 ALK CDKN2A CEACAM5 CLDN1 EGFR HRAS
3 neoplasm MP:0002006 10.13 ALK CDKN2A CEACAM5 EGFR HRAS KRAS
4 endocrine/exocrine gland MP:0005379 10.1 ALK CDKN2A CEACAM5 EGFR HRAS INSM1
5 no phenotypic analysis MP:0003012 10.06 CDKN2A EGFR HRAS INSM1 KRAS NKX2-1
6 muscle MP:0005369 10.03 CDKN2A CEACAM5 EGFR HRAS KRAS PDPN
7 pigmentation MP:0001186 9.97 ALK CDKN2A EGFR KRAS TP53 U2AF1
8 digestive/alimentary MP:0005381 9.96 CDKN2A CEACAM5 EGFR HRAS INSM1 KRAS
9 respiratory system MP:0005388 9.81 ALK CDKN2A EGFR HRAS INSM1 KRAS
10 mortality/aging MP:0010768 9.8 ALK CDKN2A CEACAM5 CLDN1 EGFR HRAS
11 integument MP:0010771 9.28 ALK CDKN2A CLDN1 EGFR HRAS KRAS

Drugs & Therapeutics for Adenocarcinoma in Situ

Drugs for Adenocarcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 18)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 4
2 Immunologic Factors Phase 3
3
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
4
Testosterone Approved, Investigational Phase 1, Phase 2 58-22-0 5408 6013
5
Sargramostim Approved, Investigational Phase 1, Phase 2 123774-72-1
6
Metformin Approved Phase 2 1115-70-4, 657-24-9 4091
7
Molgramostim Investigational Phase 1, Phase 2 99283-10-0
8 Alkylating Agents Phase 1, Phase 2
9 Antirheumatic Agents Phase 1, Phase 2
10 Antineoplastic Agents, Alkylating Phase 1, Phase 2
11 Hormones Phase 1, Phase 2
12 Androgens Phase 1, Phase 2
13 Immunosuppressive Agents Phase 1, Phase 2
14 Hypoglycemic Agents Phase 2
15
Proflavine Approved 92-62-6 7099
16 Anti-Infective Agents
17 Pharmaceutical Solutions
18 Anti-Infective Agents, Local

Interventional clinical trials:

(show all 14)
# Name Status NCT ID Phase Drugs
1 A Phase IV Open-Label, Descriptive Study to Evaluate the Safety and Effectiveness on the Incidence of HPV 6, 11, 16 and 18 Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 26-Year-Old Japanese Women Completed NCT01544478 Phase 4
2 Comparison of Video-assisted Thoracoscopic Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion Unknown status NCT02011997 Phase 3
3 A Phase III Open-label Safety and Immunogenicity Study of GARDASIL™9 Administered to 9- to 26-Year-Old Females and Males in Vietnam Completed NCT03546842 Phase 3
4 A Double-Blind, Controlled, Randomized, Phase III Study of the Efficacy of an HPV16/18 VLP Vaccine in the Prevention of Advanced Cervical Intraepithelial Neoplasia (CIN2, CIN3, Adenocarcinoma In Situ [AIS] and Invasive Cervical Cancer) Associated With HPV 16 or HPV 18 Cervical Infection in Healthy Young Adult Women in Costa Rica. Completed NCT00128661 Phase 3
5 A Phase 3 Open-Label Clinical Trial to Study the Immunogenicity, Safety and Tolerability of Recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years Active, not recruiting NCT03493542 Phase 3
6 A Neoadjuvant Immunologic Study of Androgen Deprivation Therapy Combined With a Granulocytemacrophage-colony Stimulating Factor F-secreting Allogeneic Prostate Cancer Vaccine and Low-dose Cyclophosphamide in Men With High-risk Localized Prostate Cancer Undergoing Radical Prostatectomy Completed NCT01696877 Phase 1, Phase 2 degarelix acetate;Cyclophosphamide;GVAX
7 Metformin With Neoadjuvant Chemoradiation to Improve Pathologic Responses in Rectal Cancer: An Internal Pilot Study Completed NCT03053544 Phase 2 Metformin
8 Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix Completed NCT02206048 Proflavine
9 Prevalence of Anal Dysplasia and Anal Cancer in Women With Cervical, Vaginal and Vulvar Dysplasia and Cancer Recruiting NCT02140021
10 Clinical Evaluation Study of Urine hrHPV Detection for the Diagnosis of Presence of Cervical HPV and Correlation of Cervical Lesions Recruiting NCT05210348
11 CT-based Radiomic Algorithm for Assisting Surgery Decision and Predicting Immunotherapy Response of NSCLC Recruiting NCT04452058
12 HSIL/ACIS/Early Cervical Cancer: What Are The Current Causative HPV Subtypes in the Era of HPV Vaccination? Recruiting NCT02937155
13 Effectiveness of Cervical Screening in Unvaccinated, Herd Effect Protected Women - A Randomized Trial Enrolling by invitation NCT04755517
14 Primary Cervical Cancer Screening by Self-sampling HPV Test Not yet recruiting NCT05613283

Search NIH Clinical Center for Adenocarcinoma in Situ

Cochrane evidence based reviews: adenocarcinoma in situ

Genetic Tests for Adenocarcinoma in Situ

Anatomical Context for Adenocarcinoma in Situ

Organs/tissues related to Adenocarcinoma in Situ:

MalaCards : Cervix, Lung, Prostate, Lymph Node, Smooth Muscle, Colon, Pancreas

Publications for Adenocarcinoma in Situ

Articles related to Adenocarcinoma in Situ:

(show top 50) (show all 1489)
# Title Authors PMID Year
1
HPV type-specific trends in cervical precancers in the United States, 2008 to 2016. 62
35904861 2023
2
Older women testing positive for HPV 16/18 on cervical screening and risk of high-grade cervical abnormality. 62
36468183 2022
3
Adenocarcinoma in situ or early-stage cervical cancer is a risk factor for preterm delivery after cervical conization: a multicenter observational study. 62
35341455 2022
4
Ten-year follow-up of lung cancer patients with resected adenocarcinoma in situ or minimally invasive adenocarcinoma: Wedge resection is curative. 62
35965138 2022
5
Evolution of lung adenocarcinoma from preneoplasia to invasive adenocarcinoma. 62
36325966 2022
6
Delineating the dynamic evolution from preneoplasia to invasive lung adenocarcinoma by integrating single-cell RNA sequencing and spatial transcriptomics. 62
36434043 2022
7
Comparison of the safety between cervical conization and hysterectomy for patients with cervical adenocarcinoma in situ. 62
36424703 2022
8
Use of a radiofrequency identification system for precise sublobar resection of small lung cancers. 62
36401101 2022
9
Uniportal video-assisted thoracic surgery basal segmentectomy: a single-center retrospective cohort study. 62
36386453 2022
10
Conservative Treatment for Cervical Adenocarcinoma In Situ: Long-Term Results. 62
35917498 2022
11
Predictors of treatment failure for adenocarcinoma in situ of the uterine cervix: Up to 14 years of recorded follow-up. 62
36168314 2022
12
Benign stratified intraepithelial mucinous proliferation of the uterine cervix: Significance of a previously unreported potential mimic of SMILE. 62
35988376 2022
13
Diagnostic utility of ThinPrep Imaging System® for detecting atypical glandular cells in cervical smear samples. 62
36308412 2022
14
HPV-genotyping versus conventional cervical cytology as a screening method to detect dysplastic cervical epithelial changes. 62
36280748 2022
15
Incidence of cervical precancerous lesions and cervical cancer in Denmark from 2000 to 2019: Population impact of multi-cohort vaccination against human papillomavirus infection. 62
36250312 2022
16
Structure-based classification of EGFR mutations in operable pre-invasive and invasive non-small cell lung cancer: a cross-sectional study. 62
36245625 2022
17
α-cyanoacrylate rapid medical adhesive (medical EC glue) localization of pulmonary nodules guided by computed tomography before thoracoscopic surgery. 62
36125820 2022
18
Association between quantitative spectral CT parameters, Ki-67 expression, and invasiveness in lung adenocarcinoma manifesting as ground-glass nodules. 62
36131377 2022
19
Corrigendum to "False-Negative Pap Tests in Women with Biopsy-Proven Invasive Endocervical Adenocarcinoma/Adenocarcinoma In Situ: A Retrospective Analysis with Assessment of Inter-Observer Agreement" Journal of the American Society of Cytopathology 2021;11:3-12. 62
36114101 2022
20
Endocervical Adenocarcinoma: Comprehensive Histological Review and Re-classification of 123 Consecutive Cases According to the Updated World Health Organization Classification of Female Genital Tumors. 62
36039458 2022
21
Cytopathologic features of human papillomavirus-independent, gastric-type endocervical adenocarcinoma. 62
36128862 2022
22
Low-grade Neuroendocrine Tumor of the Cervix: Report of 3 Cases of a Rare Neoplasm With Review of the Literature. 62
35075048 2022
23
A Nomogram Incorporating Tumor-Related Vessels for Differentiating Adenocarcinoma In Situ from Minimally Invasive and Invasive Adenocarcinoma Appearing as Subsolid Nodules. 62
36150965 2022
24
The value of the endocervical margin status in LEEP: analysis of 610 cases. 62
35220477 2022
25
Investigation on the incidence and risk factors of lung cancer among Chinese hospital employees. 62
35818719 2022
26
Quantitative CT imaging analysis to predict pathology features in patients with a congenital pulmonary airway malformation. 62
34809963 2022
27
The prognostic impact of lung adenocarcinoma predominance classification relating to pathological factors in lobectomy, the Japanese Joint Committee of Lung Cancer Registry Database in 2010. 62
35948946 2022
28
Computed Tomography Findings for Predicting Invasiveness of Lung Adenocarcinomas Manifesting as Pure Ground-Glass Nodules. 62
35840350 2022
29
A triple-classification for the evaluation of lung nodules manifesting as pure ground-glass sign: a CT-based radiomic analysis. 62
35896975 2022
30
[Development and task of gynecologic pathology]. 62
35785827 2022
31
Cervical adenocarcinoma in situ during pregnancy and subsequent fertility-sparing therapy challenge. 62
34559882 2022
32
Predictors of Invasiveness in Adenocarcinoma of Lung with Lepidic Growth Pattern. 62
35893116 2022
33
Correlation of computed tomography quantitative parameters with tumor invasion and Ki-67 expression in early lung adenocarcinoma. 62
35758369 2022
34
[Global guidelines for cervical cancer and precancerous lesions treatment: a systematic review]. 62
35692019 2022
35
Minimally Invasive and Sublobar Resections for Lung Cancer. 62
35671768 2022
36
Application of Mimics Medical 21.0 Software in thoracoscopic anatomical sublobectomy. 62
34160177 2022
37
The Effect of Surgeon Volume on the Outcome of Laser Vaporization: A Single-Center Retrospective Study. 62
35621692 2022
38
Indeterminate pulmonary subsolid nodules in patients with no history of cancer: growing prediction, CT pattern, and pathological diagnosis. 62
35748205 2022
39
Performance of three colposcopic images for the identification of squamous and glandular cervical precursor neoplasias. 62
34727221 2022
40
Preventing Uterine Cervix Cancer: The Clinical Meaning of Atypical Glandular Cells. 62
35139566 2022
41
Development and validation of qualitative and quantitative models to predict invasiveness of lung adenocarcinomas manifesting as pure ground-glass nodules based on low-dose computed tomography during lung cancer screening. 62
35502397 2022
42
PTEN Loss and ARID1A Mutation in an HPV-positive Metastatic Adenocarcinoma Diagnosed Almost 18 yr After an Intact Cone Excision for Endocervical Adenocarcinoma In Situ. 62
34282106 2022
43
Endocervical adenocarcinoma in situ with ovarian metastases. 62
35379705 2022
44
Clinical, Morphologic, and Molecular Features Associated With Ovarian Metastases From Pattern A Endocervical Adenocarcinomas. 62
34889854 2022
45
[Prevalence and frequencies of human papilloma virus types in adenocarcinoma in situ of the uterine cervix]. 62
35359046 2022
46
A computerized tomography-based radiomic model for assessing the invasiveness of lung adenocarcinoma manifesting as ground-glass opacity nodules. 62
35429974 2022
47
Gene expression profiling using targeted RNA-sequencing to elucidate the progression from histologically normal lung tissues to non-invasive lesions in invasive lung adenocarcinoma. 62
35067776 2022
48
Identification and evaluation of circulating small extracellular vesicle microRNAs as diagnostic biomarkers for patients with indeterminate pulmonary nodules. 62
35366907 2022
49
Intrapericardial Thymoma Presented as Pericardial Tamponade with Post-Operative Myasthenia Gravis. 62
35630026 2022
50
Adenocarcinoma in situ detected on a thin-walled lung cavity: a case report. 62
35377018 2022

Variations for Adenocarcinoma in Situ

Expression for Adenocarcinoma in Situ

Search GEO for disease gene expression data for Adenocarcinoma in Situ.

Pathways for Adenocarcinoma in Situ

Pathways related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1 12.55 TP53 SOX17 HRAS EGFR CDKN2A
2
Show member pathways
12.42 ALK CDKN2A EGFR HRAS KRAS TP53
3
Show member pathways
12.34 EGFR HRAS KRAS TP53
4
Show member pathways
12.32 TP53 KRAS HRAS EGFR
5
Show member pathways
12.29 TP53 KRAS HRAS EGFR
6 12.16 TP53 MAPK8IP1 KRAS HRAS EGFR
7
Show member pathways
12.08 TP53 KRAS HRAS EGFR
8 11.92 TP53 GP5 EGFR CLDN1
9 11.86 TP53 KRAS HRAS CLDN10 CLDN1
10
Show member pathways
11.77 KRAS HRAS EGFR
11
Show member pathways
11.64 TP53 KRAS HRAS
12 11.6 KRAS HRAS EGFR CLDN1 CDKN2A
13 11.48 KRAS HRAS EGFR
14 11.33 KRAS HRAS EGFR
15 11.27 KRAS HRAS ALK
16 11.22 TP53 KRAS HRAS EGFR CDKN2A
17 11.13 EGFR HRAS KRAS
18 11.12 TP53 KRAS HRAS EGFR
19 11.08 KRAS HRAS EGFR
20
Show member pathways
11.04 KRAS HRAS EGFR
21
Show member pathways
10.67 KRAS HRAS
22 10.62 TP53 KRAS HRAS EGFR CDKN2A

GO Terms for Adenocarcinoma in Situ

Biological processes related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.96 TP53 SOX17 NKX2-1 KRAS HRAS CDKN2A
2 positive regulation of cell migration GO:0030335 9.65 PDPN INSM1 HRAS EGFR CLDN1
3 Ras protein signal transduction GO:0007265 9.23 TP53 KRAS HRAS CDKN2A
4 positive regulation of miRNA maturation GO:1903800 9.16 TP53 EGFR

Sources for Adenocarcinoma in Situ

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....